CV

PD Dr. rer. nat. Cécile Gouttefangeas

Academic education

1988 - 1989: Diploma thesis at the INSERM Unit 93, University Paris VII, France. (head of Department: Prof. Dr. L. Degos)
1984 - 1988: Study in Biochemistry, University Paris XI, France
1984: Baccalaureat Mathématiques et Sciences de la Nature (Abitur), Académie de Versailles, France.

Scientific degrees

2023: apl professorship ("außerplanmäßige Professorin"), Eberhard Karls University, Tübingen
2016: Habilitation: Immunology, Eberhard Karls University, Tübingen (Title: Effector T cells against cancer). Supervisor: prof. Dr. Hans-Georg Rammensee.
1993: Doctorat (Dr. rer. nat./ Ph.D): INSERM Unit 93, University Paris VII, France (Title: Phenotypic and functional identifiaction of human T-lymphocyte subsets). Supervisor: Professor Dr. L. Degos/Dr. L. Boumsell.

Scientific career

2004 - present: Group leader at the Institute for Cell Biology, Department of Immunology, University of Tübingen, Germany (Immune monitoring), Teaching activities at the University of Tübingen (since 2008), Delegate for ethics matters at the Department of Immunology (2005-2018), Delegate for the DKTK immune-monitoring strategy workgroup (start 2018)
2001 - present: Scientific associate at the Institute for Cell Biology, Department of Immunology, University of Tübingen, Germany
1997 - 2001: Post-doctoral position at the Institute for Cell Biology, Department of Immunology (head Prof. H. G. Rammensee), Tübingen, Germany. (Tumor antigen-derived CD8⁺ T cell epitopes).
1994 - 1996: Post-doctoral position at the INSERM Unit 395 (head Prof. C. de Préval), Toulouse, France.

Honors/ Awards/ Memberships

Fellowships

Post-doctorate: Fellowship from the European Union (Marie Curie Program), Grants from the Association for Cancer Research (ARC) and the National League Against Cancer (LNCC).

Diploma and doctoral theses: Fellowships from the Ministry of Education and Ministry of Research, France.

Memberships

2015 - present: DGfI member.

2007 - present: Member of the Cancer Immunotherapy Consortium of the Cancer Research Institute (CIC-CRI).

2006 - present: Member of the Association for Cancer Immunotherapy (CIMT).

2005 - present: member of the steering committee, chair (2012-2013) and active participant of the CIMT Immunoguiding Program (CIP), a working group of the Association for Cancer Immunotherapy (CIMT). www.cimt.eu/workgroups/CIP.

Others

2016: Co-organization of the 1^st EMBL/DFG Women in Science Network Conference “From Genes, Cells and the Immune System towards Therapies”, 19-20 Sept 2016, Heidelberg.

Reviewer for international peer review journals (Frontiers in Oncology, Cancer Immunology Immunotherapy, International Journal of Cancer, Journal of Immunotherapy of Cancer, Vaccine…) and external reviewer for grant applications (Research Fund Denmark, ANR France, FNRS Belgium)

2011: Medizindidaktische Qualifikation I, Kompetenzzentrum für Hochschuldidaktik in Medizin, Baden-Württemberg.

Patents

Co-inventor of international patents on HLA-peptides and T-cell epitopes derived of (WO/2009/138236, WO/2011/073215, WO2012079878), and adjuvants (WO2018211113)

Contact Information

Prof. (apl) Dr. rer. nat. Cécile Gouttefangeas

Group Leader

University of Tübingen

Institute for Immunology

Curriculum Vitae (CV)

10 most relevant publications

Maia A, Schuhmacher J, Nadalin S, Königsrainer A, Thiel K, Nelde A, Zinser RS, Schroeder C, Mattern S, Singer S, Bösmüller H, Rammensee HG, Löffler MW*, Gouttefangeas C*. Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case. J Immunother Cancer. 2025;13(10):e012107. doi:10.1136/jitc-2025-012107 *contributed equally
Talpin A, Maia A, Carpier JM, Kulakowski G, Aubergeon L, Kervevan J, Gaal C, Strozzi F, Billerey C, Amable L, Mersceman T, Garnier A, Oliveira C, Calderon C, Bachrouche D, Ventujol C, Bernard L, Manteau A, Martinez J, Bonnet M, Noguerol J, Laviolette K, Boullerot L, Malfroy M, Chevalier G, Adotevi O, Joffre O, Idbaih A, Vieito M, Ghiringhelli F, Stradella A, Tabatabai G, Burger MC, Mildenberger I, Herrlinger U, Reardon DA, Wick W, Gouttefangeas C, Bonny C, Chene L, Gamelas Magalhaes J. Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer. J Immunother Cancer. 2025;13(2):e010192. doi:10.1136/jitc-2024-010192
Lemke S, Dubbelaar ML, Zimmermann P, Bauer J, Nelde A, Hoenisch Gravel N, Scheid J, Wacker M, Jung S, Dengler A, Maringer Y, Rammensee HG, Gouttefangeas C, Fillinger S, Bilich T, Heitmann JS, Nahnsen S, Walz JS. PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development. J Immunother Cancer. 2025;13(4):e011366. doi:10.1136/jitc-2024-011366
Schöllhorn A, Maia A, Kimmerle F, Born J, Rammensee HG, Dimitrov S*, Gouttefangeas C*. Staining of activated ß₂-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells. Front Immunol. 2023;13. doi:10.3389/fimmu.2022.1107366 *contributed equally
Schuhmacher J, Heidu S, Balchen T, Richardson JR, Schmeltz C, Sonne J, Schweiker J, Rammensee HG, Thor Straten P, Røder MA, Brasso K, Gouttefangeas C. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J Immunother Cancer. 2020;8(2):e001157. doi:10.1136/jitc-2020-001157
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240-245. doi:10.1038/s41586-018-0810-y
Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C. PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma. Cancer Immunol Res. 2019;7(11):1891-1899. doi:10.1158/2326-6066.CIR-19-0146
Dimitrov S*, Gouttefangeas C*, Besedovsky L, Jensen ATR, Chandran PA, Rusch E, Businger R, Schindler M, Lange T, Born J, Rammensee HG. Activated integrins identify functional antigen-specific CD8 + T cells within minutes after antigen stimulation. Proceedings of the National Academy of Sciences. 2018;115(24). doi:10.1073/pnas.1720714115 *corresponding authors
Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C. Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas. Cancer Res. 2009;69(21):8412-8419. doi:10.1158/0008-5472.CAN-09-0852
Britten CM*, Gouttefangeas C*, Welters MJP, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunology, Immunotherapy. 2008;57(3):289-302. doi:10.1007/s00262-007-0378-0 (Open access) *contributed equally

CV